October 2022—Oxford Immunotec, a division of PerkinÂElmer, announced FDA approval of its T-Cell Select reagent kit for automating the company’s T-Spot.TB test workflow for in vitro diagnostic use by certified laboratories.
Read More »FDA approves T-Cell Select to automate TB testing
Sept. 22, 2022—Oxford Immunotec, a division of PerkinElmer, announced FDA approval of its T-Cell Select reagent kit for automating the company’s T-SPOT.TB test workflow for in vitro diagnostic use by certified laboratories.
Read More »Oxford Immunotec submits EUA for T-SPOT.COVID test
March 17, 2021—Oxford Immunotec has released the T-SPOT.COVID test, a CE-marked ELISpot-based test intended for qualitative detection of T-cell immune response to SARS-CoV-2 in human whole blood.
Read More »Oxford Immunotec releases SARS-CoV-2 kit
July 2020—Oxford Immunotec announced the release of the research use only T-Spot Discovery SARS-CoV-2 test kit.
Read More »Oxford Immunotec releases T-Spot Discovery SARS-CoV-2 kit
May 20, 2020—Oxford Immunotec announced the release of the research use only T-Spot Discovery SARS-CoV-2 test kit.
Read More »FDA clears donor screening tests for B. microti infection, 5/18
May 2018—The FDA approved Oxford Immunotec’s Imugen Babesia microti arrayed fluorescent immunoassay for the detection of antibodies to Babesia microti in human plasma samples and the Imugen Babesia microti nucleic acid test for the detection of B. microti DNA in human whole blood samples.
Read More »FDA OKs screening tests for tick-borne parasite
March 19, 2018—The FDA approved Oxford Immunotec’s Imugen Babesia microti arrayed fluorescent immunoassay for the detection of ...
Read More »Cytomegalovirus test, 6/15
June 2015—Oxford Immunotec announced the availability in the United States of a test that measures the strength of a patient’s cellular immune response to cytomegalovirus. The T-Spot.CMV test is available as a laboratory-developed test from the company’s CLIA-certified and CAP-accredited service laboratory.
Read More »